An Efficacy and Safety Study of ICP-192 in Subjects With Bladder Urothelial Cancer

NCT04492293 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

115

Enrollment

INDUSTRY

Sponsor class

Conditions

Bladder Urothelial Cancer

Interventions

DRUG: ICP-192

Sponsor

Beijing InnoCare Pharma Tech Co., Ltd.